Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 1.533
Filtrer
1.
Rom J Ophthalmol ; 68(2): 191-197, 2024.
Article de Anglais | MEDLINE | ID: mdl-39006336

RÉSUMÉ

Lacrimal gland lymphomas are rare orbital tumors, constituting a minor fraction of all orbital and ocular adnexal malignancies. This case study presents an 83-year-old male with bilateral lacrimal gland tumors, more prominent in the left orbit, causing decreased visual acuity, red eye, excessive tearing, and diplopia. Initial ophthalmological evaluations and imaging suggested bilateral lacrimal gland lymphoma, confirmed by histopathology as diffuse large B-cell non-Hodgkin lymphoma of the MALT type. Due to the significant tumor size and risk of visual function loss, surgical intervention was performed, followed by corticosteroid therapy. Postoperatively, a marked improvement in symptoms and a reduction in tumor size were observed. This case underscores the importance of comprehensive diagnostic approaches, including clinical, imaging, and histopathological evaluations, highlighting the need for a multidisciplinary approach in managing rare orbital tumors like lacrimal gland lymphoma. The patient's postoperative and follow-up care included oncological management to monitor and ensure long-term disease control and patient well-being. Abbreviations: RE = right eye, LE = left eye, CT = Computer tomography, MRI = Magnetic Resonance Imaging, TOD = intraocular pressure of right eye, TOS = intraocular pressure of left eye, US = ultrasound.


Sujet(s)
Maladies de l'appareil lacrymal , Imagerie par résonance magnétique , Tomodensitométrie , Humains , Mâle , Sujet âgé de 80 ans ou plus , Maladies de l'appareil lacrymal/diagnostic , Maladies de l'appareil lacrymal/chirurgie , Tumeurs de l'oeil/diagnostic , Tumeurs de l'oeil/chirurgie , Tumeurs de l'oeil/thérapie , Appareil lacrymal/anatomopathologie , Appareil lacrymal/chirurgie , Appareil lacrymal/imagerie diagnostique , Lymphome B diffus à grandes cellules/diagnostic , Lymphome B diffus à grandes cellules/chirurgie , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/chirurgie , Acuité visuelle , Procédures de chirurgie ophtalmologique/méthodes , Biopsie
2.
Zhonghua Xue Ye Xue Za Zhi ; 45(5): 495-499, 2024 May 14.
Article de Chinois | MEDLINE | ID: mdl-38964925

RÉSUMÉ

Objective: To investigate the clinical characteristics, diagnosis, treatment, and prognosis of primary thyroid lymphoma (PTL) . Methods: A retrospective analysis was conducted on the clinical and pathological data of 34 newly diagnosed PTL patients admitted to Beijing Tongren Hospital from September 2010 to February 2023. The Kaplan-Meier survival curve and Log-rank test were used for survival analysis, and the Cox regression model was applied for univariate analysis of prognostic factors. Results: All 34 PTL patients presented with cervical mass as the initial clinical manifestation. There were 9 males and 25 females. The pathological diagnosis was diffuse large B-cell lymphoma (DLBCL) in 29 patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 5 patients. Among the DLBCL patients, 6 had B symptoms, 17 had an Eastern Cooperative Oncology Group (ECOG) score of ≥2, the Ann Arbor staging was stage Ⅰ-Ⅱ in 21 cases and stage Ⅲ-Ⅳ in 8 cases, the tumor diameter was ≥10 cm in 4 cases, and 14 had concurrent Hashimoto thyroiditis; 27 cases received chemotherapy, with 21 cases achieving complete remission (CR), 2 cases partial remission (PR), and 6 cases of disease progression; the 5-year progression-free survival and overall survival rates were 78.9% and 77.4%, respectively; univariate survival analysis showed that B symptoms, tumor diameter ≥10 cm, and Ann Arbor stage Ⅲ-Ⅳ were significant factors affecting patient prognosis (P<0.05). MALT lymphoma patients were all in stages Ⅰ-Ⅱ, had an ECOG score of 0-1, and were without B symptoms. All patients underwent surgical resection, with 4 cases achieving CR and 1 case PR. Conclusion: PTL is more common in females with concurrent Hashimoto thyroiditis, with the majority of pathological types being B-cell lymphoma. The main treatment is chemotherapy, supplemented by radiotherapy and surgery, and the prognosis is relatively favorable.


Sujet(s)
Lymphome B de la zone marginale , Lymphome B diffus à grandes cellules , Tumeurs de la thyroïde , Humains , Mâle , Femelle , Études rétrospectives , Pronostic , Tumeurs de la thyroïde/diagnostic , Tumeurs de la thyroïde/anatomopathologie , Tumeurs de la thyroïde/thérapie , Lymphome B diffus à grandes cellules/diagnostic , Lymphome B diffus à grandes cellules/thérapie , Lymphome B diffus à grandes cellules/anatomopathologie , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/thérapie , Lymphome B de la zone marginale/anatomopathologie , Taux de survie , Adulte d'âge moyen , Adulte
3.
Front Endocrinol (Lausanne) ; 15: 1372661, 2024.
Article de Anglais | MEDLINE | ID: mdl-38883595

RÉSUMÉ

The mucosa-associated lymphoid tissue (MALT) lymphoma subtype, specifically extranodal marginal zone B-cell lymphoma, is a rare variant. Within this subtype, primary thyroid MALT lymphoma is an uncommon occurrence. The literature provides limited documentation on thyroid MALT lymphomas, as their prevalence is comparatively lower than in other organ sites. The coexistence of papillary thyroid carcinoma (PTC) and thyroid MALT lymphomas is exceedingly rare. It presents a rare case of primary thyroid MALT lymphoma accompanied by PTC, thyroid lymphoma not being considered before surgery. A 64-year-old female patient, who had been experiencing symptoms related to a substantial thyroid tumor for a duration of three years, she refused to do a needle biopsy before surgery and expressed a preference for surgical resection. Consequently, the patient underwent a total thyroidectomy along with lymphadenectomy of the central compartment. A histological examination subsequently confirmed the presence of papillary thyroid carcinoma (PTC) and mucosa-associated lymphoid tissue (MALT) lymphoma. Due to the favorable response of the MALT lymphoma to local treatment and the absence of metastasis in other organs, no further treatment was administered for the MALT lymphoma following the surgery. Currently, the patient exhibits no signs of tumor recurrence based on ultrasound and laboratory evaluations. We also provide an overview of the clinical findings on PTC and MALT lymphoma patients already reported and discuss the possible treatment strategy.


Sujet(s)
Lymphome B de la zone marginale , Cancer papillaire de la thyroïde , Tumeurs de la thyroïde , Humains , Lymphome B de la zone marginale/anatomopathologie , Lymphome B de la zone marginale/chirurgie , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/thérapie , Femelle , Adulte d'âge moyen , Tumeurs de la thyroïde/anatomopathologie , Tumeurs de la thyroïde/chirurgie , Cancer papillaire de la thyroïde/anatomopathologie , Cancer papillaire de la thyroïde/chirurgie , Thyroïdectomie , Tumeurs primitives multiples/anatomopathologie , Tumeurs primitives multiples/chirurgie
4.
Intern Med J ; 54(6): 1017-1030, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38881453

RÉSUMÉ

Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.


Sujet(s)
Lymphome B de la zone marginale , Humains , Australie , Consensus , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/thérapie , Nouvelle-Zélande
5.
Inn Med (Heidelb) ; 65(7): 690-700, 2024 Jul.
Article de Allemand | MEDLINE | ID: mdl-38833003

RÉSUMÉ

Mucosa-associated lymphomas of the gastrointestinal tract are a heterogeneous group differing in pathogenesis, localization and therapeutic options. For all of them, differentiated treatment requires an exact determination of lymphoma stage. For gastric MALT lymphoma, the pathogenetic role of Helicobacter pylori infection has become evident in the last 30 years. These insights were consequently implemented into clinical practice. Nowadays, Helicobacter pylori eradication is the treatment of choice for gastric MALT lymphoma, leading to complete remission of the lymphoma in the majority of cases. In the absence of success, radiotherapy is available in localized stages I/II E with excellent results. Immuno-chemotherapy is the domain for advanced stages III/IV E, and surgery plays no role any more. The rare intestinal and colorectal MALT lymphomas require an individualized therapeutic approach.


Sujet(s)
Infections à Helicobacter , Lymphome B de la zone marginale , Humains , Association thérapeutique , Tumeurs gastro-intestinales/thérapie , Tumeurs gastro-intestinales/anatomopathologie , Infections à Helicobacter/complications , Infections à Helicobacter/traitement médicamenteux , Helicobacter pylori , Lymphome B de la zone marginale/thérapie , Lymphome B de la zone marginale/anatomopathologie , Lymphome B de la zone marginale/microbiologie , Lymphome B de la zone marginale/diagnostic , Stadification tumorale , Tumeurs de l'estomac/thérapie , Tumeurs de l'estomac/anatomopathologie
6.
Arch Dermatol Res ; 316(5): 199, 2024 May 22.
Article de Anglais | MEDLINE | ID: mdl-38775835

RÉSUMÉ

BACKGROUND: Following the initial diagnosis of a marginal zone or follicle center lymphoma on skin biopsy, patients undergo staging to determine the extent of disease. OBJECTIVE: We sought to characterize the frequency that these patients were found to have a systemic nodal disease upon work-up as well as the impact of imaging on disease management. METHODS: We conducted a retrospective chart review of patients presenting with a working diagnosis of PCMZL or PCFCL treated at The Ohio State University from 1990 to 2022. Data collected included: patient history, progress notes, virtual encounters, laboratory results, presentation features, imaging, and pathology. Biomarkers included ANA, SSA/SSB, BCL6 and H. Pylori labs, bone marrow biopsies, positive imaging, and need of systemic medication and mortality. RESULTS: 71 patients with suspected PCMZL and PCFCL were identified. 66 of 71 patients underwent imaging. Of this group, 12 patients (9 with suspected PCFCL and 3 with suspected PCMZL) demonstrated lymphadenopathy on imaging. Of these 12 patients, 5 underwent biopsy of suspected lymph nodes, and 3 had biopsy-proven nodal involvement and received systemic therapy. Of the remaining 7 patients with evidence of lymphadenopathy on imaging, 4 were thought to have reactive lymph nodes, and 3 were treated empirically with systemic chemotherapy due to the extent or progression of their disease. Of patients with imaging negative for lymphadenopathy, 3 of 52 (5.8%) patients with received systemic treatment, while 49 of 52 patients (94.2%) received localized treatment. LIMITATIONS: Most of the relationships between this data were correlational and patients selected for this study were limited to a single institution. CONCLUSION: Prospective study of the role of imaging without subsequent lymph biopsy to direct treatment decisions is warranted.


Sujet(s)
Lymphadénopathie , Tumeurs cutanées , Humains , Mâle , Études rétrospectives , Femelle , Adulte d'âge moyen , Lymphadénopathie/diagnostic , Lymphadénopathie/anatomopathologie , Sujet âgé , Tumeurs cutanées/diagnostic , Tumeurs cutanées/thérapie , Tumeurs cutanées/anatomopathologie , Biopsie , Adulte , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/thérapie , Lymphome B de la zone marginale/anatomopathologie , Noeuds lymphatiques/anatomopathologie , Peau/anatomopathologie , Sujet âgé de 80 ans ou plus , Lymphome folliculaire/diagnostic , Lymphome folliculaire/anatomopathologie , Lymphome folliculaire/thérapie , Lymphome folliculaire/traitement médicamenteux , Stadification tumorale
7.
Folia Neuropathol ; 62(1): 102-107, 2024.
Article de Anglais | MEDLINE | ID: mdl-38741437

RÉSUMÉ

MALT lymphoma of the dura is a very rare type of low-grade B-cell lymphoma. Little more than 100 cases have been reported in the literature to date. We report a 43-year-old woman who was referred to hospital because of a series of three tonic-clonic seizures on the day of admission. Neurological examination revealed confusion and aphasia. Magnetic resonance imaging (MRI) showed a contrast-enhanced, broad-based lesion along the dura in the left parieto-occipital area. The suspicion of an en plaque meningioma was raised. The tumour invaded the brain parenchyma with visible extension into the brain sulci. There was a marked brain oedema surrounding the lesion and causing the midline shift 8 mm to the right. After stabilization of neurological condition (intravenous diuretics and steroids), the operation was performed. The diagnosis of dural MALT lymphoma was established. During the pathological examination, it was especially problematic to distinguish MALT lymphoma from follicular lymphoma, but the final diagnosis was MALT lymphoma. Surgical partial removal with additional R-CVP immunochemotherapy (rituximab, cyclophosphamide, vincristine and prednisone) resulted in complete remission. The follow-up period is 1 year. Our presented case of a MALT lymphoma highlights the fact that surgical partial removal with additional immunochemotherapy is an available option in these rare intracranial tumours.


Sujet(s)
Dure-mère , Lymphome B de la zone marginale , Tumeurs des méninges , Méningiome , Humains , Lymphome B de la zone marginale/anatomopathologie , Lymphome B de la zone marginale/diagnostic , Femelle , Adulte , Méningiome/anatomopathologie , Méningiome/diagnostic , Dure-mère/anatomopathologie , Tumeurs des méninges/anatomopathologie , Tumeurs des méninges/diagnostic , Diagnostic différentiel
8.
Medicine (Baltimore) ; 103(21): e38303, 2024 May 24.
Article de Anglais | MEDLINE | ID: mdl-38787969

RÉSUMÉ

RATIONALE: The most common subtype of primary lymphoma of the ocular adnexa is the mucosa-associated lymphoid tissue (MALT) subtype. MALT lymphoma of the lacrimal gland is relatively rare among the lacrimal gland tumors, and the early clinical symptoms are atypical, which can easily lead to misdiagnosis and missed diagnosis. Here, we report a case of MALT lymphoma of the lacrimal gland and explore its clinical manifestations, pathological characteristics, management, and pathogenesis, with the aim of helping clinicians gain an in-depth understanding of ocular adnexal MALT lymphoma. PATIENT CONCERNS: A 60-year-old man presented to our hospital with proptosis and diplopia. The right eye deviated and shifted toward the lower part of the nose. DIAGNOSIS: Orbital enhanced magnetic resonance imaging suggested a mass with a maximum cross-section of 3.2 × 2.1 cm. T1 weighted image was isointense, and the enhancement was more uniform and obvious. INTERVENTIONS: The right orbital mass was treated surgically, and the final pathology report was MALT lymphoma. After the pathological report was released, the patient was transferred to the hematology department for further diagnosis and no further treatment was given eventually. OUTCOMES: Seven months later, the patient did not complain of discomfort. Whole-body positron emission tomography-computed tomography, superficial lymph node examination and orbital magnetic resonance imaging revealed no abnormal changes. LESSONS: The clinical manifestations of MALT lymphoma are heterogeneous. Imaging examination is important for assessing the size of the tumor and its relationship with adjacent tissues. Postoperative pathological examination may provide further evidence for the evaluation of the patient's surgical efficacy and prognosis. Management of MALT lymphoma of the lacrimal gland requires a multidisciplinary approach involving ophthalmologists, hematologists, and radiotherapists.


Sujet(s)
Tumeurs de l'oeil , Appareil lacrymal , Lymphome B de la zone marginale , Humains , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/anatomopathologie , Lymphome B de la zone marginale/thérapie , Lymphome B de la zone marginale/imagerie diagnostique , Adulte d'âge moyen , Mâle , Tumeurs de l'oeil/diagnostic , Tumeurs de l'oeil/anatomopathologie , Tumeurs de l'oeil/thérapie , Appareil lacrymal/anatomopathologie , Appareil lacrymal/imagerie diagnostique , Imagerie par résonance magnétique , Maladies de l'appareil lacrymal/diagnostic
9.
J Clin Exp Hematop ; 64(2): 86-96, 2024 Jun 27.
Article de Anglais | MEDLINE | ID: mdl-38684405

RÉSUMÉ

To elucidate long-term outcome in primary conjunctival lymphoma, a review was conducted of 31 consecutive patients: 21 men and 10 women with an age range of 28 to 85 (median, 61) years at presentation and follow-up periods ranging from 1 to 19 (median, 7) years. Conjunctival lymphoma was on the right side in 10 patients, on the left side in 12, and on both sides in 9. Upper, lower, or both fornix lesions in 28 patients were all diagnosed as extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), while thick nasal bulbar conjunctival lesions in 3 patients were differently diagnosed as MALT lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma, respectively. Seven patients underwent local radiation (30 Gy): as initial treatment in 5 patients and treatment for relapse in 2 patients. The remaining 24 patients were observed without additional treatment after excisional biopsy: 5 of these 24 patients showed relapse 0.5 to 6 years later and underwent excisional biopsy again that revealed MALT lymphoma. Of the 5 patients with relapse, only one with second-time relapse underwent radiation. Fluorodeoxyglucose positron emission tomography was performed in 18 patients and showed no systemic lesions: high uptake was noted in the residual conjunctival lesions of 4 patients and in the relapsed conjunctival lesions of 3 patients. One patient died of rectal cancer while no patients died of lymphoma. Observation is an option in patients with primary conjunctival lymphoma after excisional biopsy. Radiation is a treatment option in the case of relapse.


Sujet(s)
Tumeurs de la conjonctive , Lymphome B de la zone marginale , Humains , Mâle , Femelle , Adulte d'âge moyen , Tumeurs de la conjonctive/anatomopathologie , Tumeurs de la conjonctive/thérapie , Tumeurs de la conjonctive/diagnostic , Sujet âgé , Adulte , Sujet âgé de 80 ans ou plus , Lymphome B de la zone marginale/anatomopathologie , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/mortalité , Lymphome B de la zone marginale/thérapie , Lymphome B de la zone marginale/radiothérapie , Biopsie , Récidive tumorale locale/anatomopathologie , Études de suivi , Récidive
10.
J Investig Med High Impact Case Rep ; 12: 23247096241244732, 2024.
Article de Anglais | MEDLINE | ID: mdl-38577998

RÉSUMÉ

Macrophage activation syndrome (MAS) is a form of secondary hemophagocytic lymphohistiocytosis (HLH) when it occurs in the context of rheumatologic disorders. HLH is a rare and potentially life-threatening syndrome characterized by excessive immune system activation. It is mainly seen in children and can be genetic based or related to infections, malignancies, rheumatologic disorders, or immunodeficiency syndromes. MAS can present with nonspecific symptoms, leading to a delay in diagnosis. This report describes a case of a 64-year-old female with marginal zone lymphoma and systemic lupus erythematosus who presented with a purpuric rash and acute kidney injury. She underwent a kidney biopsy and was diagnosed with MAS. This case highlights the importance of promptly recognizing MAS's symptoms and signs, allowing timely diagnosis and early therapeutic intervention. This potentially fatal condition tends to respond well to rapid treatment initiation with corticosteroids and to address the underlying condition.


Sujet(s)
Polyarthrite rhumatoïde , Lymphohistiocytose hémophagocytaire , Lymphome B de la zone marginale , Syndrome d'activation macrophagique , Femelle , Humains , Adulte d'âge moyen , Hormones corticosurrénaliennes/usage thérapeutique , Polyarthrite rhumatoïde/complications , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/étiologie , Lymphome B de la zone marginale/complications , Lymphome B de la zone marginale/diagnostic , Syndrome d'activation macrophagique/diagnostic , Syndrome d'activation macrophagique/étiologie
11.
Clin J Gastroenterol ; 17(3): 461-465, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38607542

RÉSUMÉ

A 61-year-old man present to us with continued abdominal pain without abdominal tenderness for 1 month. Blood testing showed elevated biliary enzymes and inflammation. Contrast-enhanced computed tomography (CT) revealed thickening of the transverse colon with relatively strong enhancement but no bile duct dilatation. Colonoscopy revealed localized edema and granular mucosa in the transverse colon. Fluoroscopic endoscopy exhibited the absence of haustra. Multiple biopsies were performed, but differentiation between mild inflammation and mucosa-associated lymphoid tissue (MALT) lymphoma was inconclusive. To establish a definitive diagnosis, transgastric endoscopic ultrasound-guided fine needle biopsy of the hypoechoic mass was performed. Histopathological analysis exhibited the proliferation of small-sized lymphocytes. Fluorescence in situ hybridization revealed the characteristic API2-MALT1 translocation of MALT lymphoma. We performed liver biopsy to investigate biliary enzyme elevation. Histopathology confirmed lymphocytic infiltration within Glisson's capsule. Immunohistochemistry showed positive for CD20 and negative for CD3 and CD5, signifying the infiltration of MALT lymphoma in the liver. Based on these findings, we diagnosed MALT lymphoma, Lugano classification Stage IV. We performed bendamustine-rituximab (BR)-combined therapy. After six courses of BR-combined therapy, colonoscopy revealed improvement in the lead pipe sign and CT revealed disappearance of the mass.


Sujet(s)
Côlon transverse , Tumeurs du côlon , Cytoponction sous échoendoscopie , Lymphome B de la zone marginale , Humains , Mâle , Lymphome B de la zone marginale/anatomopathologie , Lymphome B de la zone marginale/imagerie diagnostique , Lymphome B de la zone marginale/diagnostic , Adulte d'âge moyen , Côlon transverse/anatomopathologie , Côlon transverse/imagerie diagnostique , Tumeurs du côlon/anatomopathologie , Tumeurs du côlon/imagerie diagnostique , Tumeurs du côlon/diagnostic , Rituximab/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Coloscopie , Chlorhydrate de bendamustine/administration et posologie , Tomodensitométrie
12.
Eur J Gastroenterol Hepatol ; 36(6): 720-727, 2024 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-38625832

RÉSUMÉ

The purpose of this study was to explore the histopathological staging and differential diagnosis of marginal zone lymphoma in gastric mucosa-associated lymphoid tissue (MALT lymphoma). We performed detailed histomorphology and immunohistochemistry investigations as well as genetic testing on endoscopic biopsy and endoscopic mucosal resection specimens from 18 patients with gastric MALT lymphoma. We found that gastric MALT lymphoma typically begins as a small, isolated area outside the lymphoid follicular mantle zone or proliferates in a multifocal, patchy manner, gradually spreads to the interfollicular zone, forming diffuse proliferation, invades the gastric mucosal glands, and infiltrates or proliferates into the center of peripheral reactive lymphoid follicles. Abnormally proliferating lymphocytes invade the surrounding lymphoid follicles, resulting in damage, atrophy, and disappearance of their normal follicles as well as of the gastric mucosa glands, forming diffuse proliferation. Redifferentiation and proliferation lead to the transformation of lymphocytes; that is, MALT transitions into highly invasive lymphoma. Based on our findings in this study, we propose the following five stages in the process of development and progression of gastric MALT lymphoma: the stage of cell proliferation outside the lymphoid follicular mantle zone; the stage of heterogeneous proliferative lymphoepithelial lesion; the stage of reactive lymphoid follicular implantation; the stage of lymphoid follicular clonal proliferation; and the stage of MALT transforming into highly invasive lymphoma. We examined the differential diagnosis of histopathological features at each stage. The clinicopathological staging of gastric MALT lymphoma can help clinicians provide accurate treatment and track malignant cell transformation, thus playing a significant role in controlling its development and progression.


Sujet(s)
Muqueuse gastrique , Lymphome B de la zone marginale , Stadification tumorale , Tumeurs de l'estomac , Humains , Lymphome B de la zone marginale/anatomopathologie , Lymphome B de la zone marginale/diagnostic , Tumeurs de l'estomac/anatomopathologie , Tumeurs de l'estomac/diagnostic , Diagnostic différentiel , Femelle , Muqueuse gastrique/anatomopathologie , Adulte d'âge moyen , Mâle , Sujet âgé , Adulte , Biopsie , Immunohistochimie , Prolifération cellulaire , Sujet âgé de 80 ans ou plus , Gastroscopie , Mucosectomie endoscopique , Marqueurs biologiques tumoraux/analyse , Invasion tumorale
13.
Korean J Gastroenterol ; 83(4): 157-162, 2024 Apr 25.
Article de Anglais | MEDLINE | ID: mdl-38659252

RÉSUMÉ

Mucosa-associated lymphoid tissue (MALT) lymphoma, also known as extranodal marginal zone lymphoma, is a low-grade B-cell lymphoma that can develop in the mucosal layer of various organs, including the gastrointestinal tract, salivary glands, lungs, and skin. The most common site is the gastrointestinal tract, particularly the stomach. On the other hand, primary esophageal lymphomas are extremely rare. MALT lymphomas can undergo histological transformation into more aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma, resulting in a poor prognosis. This paper reports a rare case of primary esophageal MALT lymphoma mimicking a subepithelial tumor located in the lower esophagus that was treated successfully with radiotherapy. MALT lymphoma should be included in a differential diagnosis when subepithelial tumors are found in the esophagus, particularly if endoscopic ultrasonography reveals the tumor to be located in the deep mucosal and submucosal layers. Following the precise diagnosis, accurate staging and appropriate treatment are crucial. Regular follow-up is necessary to assess the possibility of recurrence or transformation to high-grade lymphoma.


Sujet(s)
Endosonographie , Tumeurs de l'oesophage , Lymphome B de la zone marginale , Tomodensitométrie , Humains , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/anatomopathologie , Tumeurs de l'oesophage/diagnostic , Tumeurs de l'oesophage/anatomopathologie , Diagnostic différentiel , Mâle , Adulte d'âge moyen
14.
J Investig Med High Impact Case Rep ; 12: 23247096241238531, 2024.
Article de Anglais | MEDLINE | ID: mdl-38494775

RÉSUMÉ

Extranodal marginal zone B-cell lymphoma (ENMZL) of mucosa-associated lymphoid tissue (MALT), a rare subtype of B-cell lymphoma, is typically associated with Helicobacter pylori (H pylori) infection, especially in gastric cases. However, this article presents 2 unique cases of H pylori-negative colonic ENMZL, challenging the conventional understanding of the disease. The first case involves an 80-year-old male diagnosed with Stage 1E ENMZL in the descending colon, and the second describes a 74-year-old male with sigmoid colon ENMZL. Both cases lacked H pylori infection, adding complexity to their management. Accompanying these case studies is a comprehensive literature review, delving into the epidemiology, pathology, clinical features, diagnosis, and treatment of H pylori-negative ENMZL, with a focus on gastrointestinal involvement. This review highlights the importance of considering H pylori-negative cases in ENMZL diagnosis and management, illustrating the need for further research and individualized treatment approaches in this uncommon lymphoma subtype.


Sujet(s)
Infections à Helicobacter , Helicobacter pylori , Lymphome B de la zone marginale , Tumeurs de l'estomac , Mâle , Humains , Sujet âgé de 80 ans ou plus , Sujet âgé , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/thérapie , Lymphome B de la zone marginale/anatomopathologie , Tumeurs de l'estomac/anatomopathologie , Infections à Helicobacter/complications , Infections à Helicobacter/traitement médicamenteux , Tissu lymphoïde/anatomopathologie
17.
BMJ Case Rep ; 17(3)2024 Mar 08.
Article de Anglais | MEDLINE | ID: mdl-38458766

RÉSUMÉ

Mucosa-associated lymphoid tissue (MALT) lymphoma is an uncommon extranodal low-grade B-cell lymphoma. Pulmonary MALT lymphomas originate from bronchial MALT and are also referred to as bronchial-associated lymphoid tissue lymphomas. MALT lymphomas of the lung are slow-growing tumours and usually present as asymptomatic chronic alveolar opacities visible on chest radiographs or with non-specific pulmonary symptoms. Here we described a case of a male patient in his early 50s with cough and chest pain for 4 years. His CT chest scan showed consolidation in the lingula and left lower lobe. Histopathology of the specimen obtained from cryobiopsy of the lung lesion showed a dense monomorphic lymphoid infiltrate, and immunohistochemistry confirmed the diagnosis of MALT lymphoma. The prognosis of pulmonary MALT lymphomas is good with >80% 5-year survival rates. This case highlights that MALT lymphoma should be considered as a differential diagnosis while evaluating cases with non-resolving consolidation.


Sujet(s)
Tumeurs des bronches , Lymphome B de la zone marginale , Pneumopathie infectieuse , Humains , Mâle , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/imagerie diagnostique , Poumon/anatomopathologie , Pneumopathie infectieuse/anatomopathologie , Tumeurs des bronches/anatomopathologie , Radiographie
18.
Breast Cancer Res Treat ; 205(2): 387-394, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38427311

RÉSUMÉ

PURPOSE: Primary Mucosa-associated lymphoid tissue (MALT) lymphoma is a rare diagnosis in the breast, and clinical diagnosis based on radiological features is often challenging. This study aimed to evaluate the clinicopathological, and radiological characteristics of the patients diagnosed with primary breast MALT lymphoma. METHODS: This study examined 18 cases of primary MALT lymphoma of the breast diagnosed at a single tertiary center between January 2002 to December 2020. Medical charts, radiological imaging and original pathology slides were reviewed for each case. RESULTS: All cases were female (gender assigned at birth) and presented with a palpable mass or an incidental imaging finding. Imaging presentation ranged from mammographic asymmetries, circumscribed masses, and ultrasound masses lacking suspicious features. Seventeen cases were biopsied under ultrasound; one received a diagnostic excision biopsy. Microscopic examination of the breast specimens demonstrated atypical small lymphocyte infiltration with plasmacytoid differentiation and rare lymphoepithelial lesions. Immunohistochemistry was performed in all cases and established the diagnosis. Most patients were treated with radiotherapy, and only three were treated with chemotherapy. The median follow-up period was 4 years and 7.5 months, and all patients were alive at the last follow-up. CONCLUSION: Primary MALT breast lymphomas are usually indolent and non-systemic, and local radiotherapy may effectively alleviate local symptoms. Radiological findings show overlap with benign morphological features, which can delay the diagnosis of this unusual etiology. Although further studies involving a larger cohort could help establish the clinical and radiological characteristics of primary breast MALT lymphomas, pathology remains the primary method of diagnosis. TRIAL REGISTRATION NUMBER: University Health Network Ethics Committee (CAPCR/UHN REB number 19-5844), retrospectively registered.


Sujet(s)
Tumeurs du sein , Lymphome B de la zone marginale , Mammographie , Humains , Lymphome B de la zone marginale/anatomopathologie , Lymphome B de la zone marginale/imagerie diagnostique , Lymphome B de la zone marginale/thérapie , Lymphome B de la zone marginale/diagnostic , Femelle , Adulte d'âge moyen , Tumeurs du sein/anatomopathologie , Tumeurs du sein/imagerie diagnostique , Tumeurs du sein/thérapie , Tumeurs du sein/diagnostic , Adulte , Sujet âgé , Études rétrospectives , Région mammaire/anatomopathologie , Région mammaire/imagerie diagnostique , Études de suivi , Biopsie
19.
Diagn Pathol ; 19(1): 49, 2024 Mar 08.
Article de Anglais | MEDLINE | ID: mdl-38459547

RÉSUMÉ

The histological diagnosis of extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) is difficult for pathologists. Recently, digital pathology systems have been widely used to provide tools that can objectively measure lesions on slides. In this study, we measured the extent of marginal zone expansion in suspected MALT lymphoma cases and compared the results with those of a molecular clonality test. In total, 115 patients who underwent an IGH gene rearrangement test for suspected MALT lymphoma were included in this study. All cases were histologically classified into three patterns; "small lymphoid aggregates with no germinal center (Pattern 1)," "lymphoid follicles with germinal center (Pattern 2)" and " fused marginal zone or diffuse small lymphocytic proliferation (Pattern 3)." The proportions of monoclonality in Pattern 1, 2, and 3 were 25.0%, 55.0%, and 97.9%, respectively. The ratios of marginal zone thickness to germinal center diameter and entire lymphoid follicle area to germinal center area were measured in Pattern 2 cases using a digital pathology system. Combining the width cutoff of 1.5 and the areal cutoff of 3.5, the sensitivity, specificity, positive predictive value, and negative predictive value for MALT lymphoma were 96.97%, 70.37%, 80.00%, and 95.00%, respectively. In conclusion, through objective measurement of the marginal zone, suspected cases of MALT lymphoma requiring a molecular clonality test can be effectively selected.


Sujet(s)
Lymphome B de la zone marginale , Humains , Lymphome B de la zone marginale/diagnostic , Lymphome B de la zone marginale/génétique , Lymphome B de la zone marginale/anatomopathologie , Sélection de patients , Lymphocytes/anatomopathologie , Tissu lymphoïde/anatomopathologie , Noeuds lymphatiques/anatomopathologie
20.
Leuk Lymphoma ; 65(6): 746-757, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38506231

RÉSUMÉ

The disease failure patterns and optimal treatment of bronchus-associated lymphoid tissue (BALT) lymphoma are unknown. This retrospective study involved 71 patients with primary BALT lymphoma who had received radiotherapy (RT), surgery, immunochemotherapy (IC), or observation. The median follow-up time was 66 months. The 5-year overall survival and lymphoma-specific survival were 91.2% and 96.1%, respectively, and were not significantly different among treatments. The 5-year cumulative incidence of overall failure for RT, surgery, IC, and observation was 0%, 9.7% (p = .160), 30.8% (p = .017), and 31.3% (p = .039). There was no grade ≥3 toxicity in RT group according to the CTCAE 5.0 reporting system. Quality of life (QoL) was at similarly good levels among the treatment groups. BALT lymphoma had a favorable prognosis but persistent risk of relapse after IC or observation. Given the very low disease failure risk and good QoL, RT remains an effective initial treatment for BALT lymphoma.


BALT lymphoma has a favorable prognosis but a persistent progression and relapse risk.Radiotherapy is associated with lower failure of disease progression and relapse, low toxicity and good quality of life.


Sujet(s)
Lymphome B de la zone marginale , Qualité de vie , Humains , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Adulte , Résultat thérapeutique , Études rétrospectives , Lymphome B de la zone marginale/thérapie , Lymphome B de la zone marginale/mortalité , Lymphome B de la zone marginale/diagnostic , Association thérapeutique/effets indésirables , Pronostic , Sujet âgé de 80 ans ou plus , Tumeurs des bronches/thérapie , Tumeurs des bronches/diagnostic , Tumeurs des bronches/mortalité , Études de suivi , Stadification tumorale
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE